A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Di, Nie, Jun, Hu, Weiheng, Dai, Ling, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689882/
https://www.ncbi.nlm.nih.gov/pubmed/32557583
http://dx.doi.org/10.1002/ijc.33161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689882/
https://www.ncbi.nlm.nih.gov/pubmed/32557583
http://dx.doi.org/10.1002/ijc.33161

Ejemplares similares